Non-Hodgkin Lymphoma: Update Bulletin # 2 [March 2019]

This edition presents key opinion leader (KOL) views on recent developments in the Non-Hodgkin Lymphoma (NHL) market. Topics covered include: Roche announcing that the US FDA had granted priority review for polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab; Roche)(BR) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL); ADC Therapeutics announcing that the first patient had been dosed in a Phase I trial assessing ADCT-402 (loncastuximab tesirine) in combination with Imfinzi (durvalumab; AstraZeneca) in advanced DLBCL, mantle cell lymphoma and follicular lymphoma (FL); Celgene announcing that the US FDA had accepted a supplemental New Drug Application and granted priority review for Revlimid (lenlidomide) in combination with rituximab (R2) for the treatment of patients with previously treated FL and marginal zone lymphoma.

Business Questions:

• What are KOL's opinions of polatuzumab vedotin in combination with BR?
• Based on the G029365 trial, how likely is polatuzumab vedotin plus BR to gain approval?
• According to KOLs how what is the most likely way in which polatuzumab vedotin will be used in NHL?
• What are KOL's reactions to ADCT-402?
• Can KOLs predict how ADCT-402, if approved, will be used in the future?
• To what extent is Revlimid currently being used in practice by KOLs?
• How do KOLs respond to the R2 AUGMENT data and what are the chances it will lead to approval?
• If approved, where will the R2 regimen most likely be used?